title: Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?
abstract: A double-blind randomized crossover design trial of carbamazepine (CBZ) and oxcarbazepine (OCBZ) was performed with 48 in-patients with epilepsy. All were stabilized on polytherapy including CBZ and had at least two seizures per week. CBZ was replaced by the trial medication. Each trial period started with a titration, followed by a 12-week steady state. Concomitant medications were kept constant during the trial. The criteria for assessment were seizure fit frequency and severity; tolerability; hematology and blood chemistry; plasma levels of antiepileptic drugs; EEG; cardiovascular parameters; and treatment preference. The following differences regarding OCBZ were detected: 9% reduction of the total number of seizures, with a significant reduction of tonic-clonic (20%) and tonic (31%) seizures; increased alertness and concentration ability in five patients; an allergic skin reaction with CBZ that completely disappeared in two patients while receiving OCBZ; an increase of valproate and phenytoin plasma levels in a number of patients, probably caused by reduced enzyme induction; a slight but significant reduction of serum Na, not causing clinical symptoms; less seizures than in the CBZ period in 25 patients (52%); and a preference for OCBZ in 23 patients (48%). We consider OCBZ at least as effective as CBZ with a slightly better tolerability. In severe cases, the wider therapeutic window might improve seizure control.
authors.affiliation: Instituut voor Epilepsiebestrijding, Heemstede, The Netherlands.
authors.forename: M A
authors.initials: MA
authors.lastname: Houtkooper
authors.forename: A
authors.initials: A
authors.lastname: Lammertsma
authors.forename: J W
authors.initials: JW
authors.lastname: Meyer
authors.forename: D M
authors.initials: DM
authors.lastname: Goedhart
authors.forename: H
authors.initials: H
authors.lastname: Meinardi
authors.forename: C A
authors.initials: CA
authors.lastname: van Oorschot
authors.forename: G F
authors.initials: GF
authors.lastname: Blom
authors.forename: R J
authors.initials: RJ
authors.lastname: Höppener
authors.forename: J A
authors.initials: JA
authors.lastname: Hulsman
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D011897:Random Allocation; D012640:Seizures / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine